ScreenerHero

ADMA ADMA Biologics, Inc.

NAS · US · Healthcare · Biotechnology · admabiologics.com
10.14USD-0.39%Mkt Cap: 2.27B $P/E: 14.49

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.27B USD
Enterprise Value2.35B USD
Revenue (TTM)512.28M USD
Gross Profit292.76M USD
Net Income (TTM)146.93M USD
Revenue/Share2.18 USD
Last Price10.14 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees640
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)14.49
P/E (Forward)10.79
PEG—
EV/EBITDA10.47
EV/Revenue4.58
P/S4.45
P/B5.62
EPS (TTM)0.70
EPS (Forward)0.94
52W Range
7.21022% of range20.46
52W High20.46 USD
52W Low7.210 USD
Profitability
Gross Margin57.39%
Oper. Margin42.16%
EBITDA Margin43.76%
Profit Margin28.80%
ROE30.78%
ROA23.54%
Growth
Revenue Growth2.00%
Earnings Growth14.30%
Cash Flow & Leverage
Operating CF50.40M USD
CapEx (TTM)22.89M USD
FCF Margin10.69%
FCF Yield2.41%
Net Debt67.82M USD
Net Debt/EBITDA0.30
Balance Sheet
Debt/Equity0.17
Current Ratio6.97
Quick Ratio3.62
Book Value/Sh1.81 USD
Cash/Share0.61 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)17.00 USD
Upside (mean)+67.7%
Target Range12.00 USD – 21.00 USD
12.00+67.7% to mean21.00
# Analysts4
Ownership
Shares Out.223.98M
Float219.66M
Insiders1.97%
Institutions92.76%
Short Interest
Short Ratio12.2d
Short % Float13.32%
Short % Out.10.81%
Shares Short24.21M
Short (prev mo.)22.68M
Technical
SMA 509.442 (+7.4%)
SMA 20011.70 (-13.4%)
Beta0.69
S&P 52W Chg16.45%
Avg Vol (30d)2.77M
Avg Vol (10d)3.15M
Technical Indicators
RSI (14)58.7
MACD0.2032
MACD Signal0.1535
MACD Hist.+0.0497
BB Upper10.47 USD
BB Middle9.629 USD
BB Lower8.791 USD
BB Width17.41%
ATR (14)0.4025 USD
Vol Ratio (20d)0.95x